Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05532345
Other study ID # 2022-P2-263-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date July 1, 2022
Est. completion date May 31, 2023

Study information

Verified date July 2023
Source Beijing Friendship Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

A retrospective, multi-center, non-interventional cohort study has been going to explore whether artificial intelligence can discriminate Drug-induced liver injury and Autoimmune hepatitis. A machine learning-based tool will be developed and validated to help clinicians to differentiate between Drug-induced liver injury and Autoimmune hepatitis


Description:

Research Objectives: 1. To develop a machine learning-based model from retrospective data. 2. To validate the machine learning-based model from internal dataset and external datasets nationwide. 3. To setup a website or application based on the above model to discriminate Drug-induced liver injury and Autoimmune hepatitis.


Recruitment information / eligibility

Status Completed
Enrollment 2583
Est. completion date May 31, 2023
Est. primary completion date May 31, 2023
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Drug-induced liver injury 1. RUCAM =6 and met one of the following biochemical conditions: a.) ALT=5 ULN, b.) or ALP =2 ULN, iii) or ALT=3 ULN and TBil=2 ULN. 2. RUCAM was between 3-5, the medical records were further reviewed by the three authors to determine the eligibility. - Autoimmune hepatitis 1. The revised International Autoimmune Hepatitis Group (IAIHG) diagnostic score=6 points. 2. Liver biopsy available, which is compatible with typical features of AIH. 3. If liver biopsy was unavailable, patients who achieved biochemical resolution after sustained immunosuppressive therapy. Exclusion Criteria: - Drug-induced liver injury 1. Hepatotropic viral infection: hepatitis A, B, C, D and E. 2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV), etc. 3. Hypoxic ischemic hepatitis and congestive liver disease. 4. Alcohol consumption: male >40g/d, female >20g/d, and =5 years. 5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis. 6. Autoimmune hepatitis. 7. Parasitic infection. 8. Sepsis. 9. Previous liver transplantation or bone marrow transplantation. 10. Pregnancy or lactation. 11. Genetic and metabolic liver diseases. - Autoimmune hepatitis 1. Hepatotropic viral infection: hepatitis A, B, C, D and E. 2. Non-hepatotropic viral infection: cytomegalovirus (CMV) and Epstein-Barr virus (EBV), etc. 3. Hypoxic ischemic hepatitis and congestive liver disease. 4. Alcohol consumption: male >40g/d, female >20g/d, and =5 years. 5. Biliary obstruction, primary biliary cholangitis; primary sclerosing cholangitis. 6. Drug-induced liver injury. 7. Parasitic infection. 8. Sepsis. 9. Previous liver transplantation or bone marrow transplantation. 10. Pregnancy or lactation. 11. Genetic and metabolic liver diseases.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Beijing Friendship Hospital, Capital Medical University Beijing

Sponsors (1)

Lead Sponsor Collaborator
Beijing Friendship Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Accuracy of the model in the differential diagnosis of DILI and AIH The ratio of the correct number of forecasts to the total number of forecasts May 31, 2023
Primary The confidence of the model in the differential diagnosis of DILI and AIH The confidence and 95% confidence internal of the model in determining whether each case is DILI or AIH May 31, 2023
See also
  Status Clinical Trial Phase
Not yet recruiting NCT06020976 - Pattern of Autoimmune Hepatitis in Children In Sohag University Hospital
Recruiting NCT05476900 - A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Autoimmune Hepatitis. Phase 2
Recruiting NCT05635266 - Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Recruiting NCT06250309 - Mediterranean Diet Versus Western Diet on Fatigue in Autoimmune Hepatitis Patients N/A
Recruiting NCT01661842 - Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Phase 1/Phase 2
Terminated NCT04339621 - AIH Risk Stratification With Multiparametric MRI
Not yet recruiting NCT04371718 - Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH) Phase 2
Completed NCT02239562 - sPIF CLINICAL STUDY PROTOCOL IN AUTOIMMUNE HEPATITIS Phase 1
Recruiting NCT05569759 - A Study of Zetomipzomib (KZR-616) in Patients With Autoimmune Hepatitis (PORTOLA) Phase 2
Completed NCT02463331 - Association of Chloroquine and Prednisone as an Alternative Treatment for Autoimmune Hepatitis Phase 4
Not yet recruiting NCT06356506 - A Study on Factors of Biochemical Response in Autoimmune Hepatitis
Terminated NCT04203875 - Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis Phase 1
Recruiting NCT06078098 - Development of a Autoimmune Hepatitis Patient's Database Linked to a Biological Sample Storage
Completed NCT00838214 - Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis Phase 2/Phase 3
Recruiting NCT05810480 - PredIcting sterOid depeNdEnt livEr injuRy With Polyreactive Immunoglobulin G
Recruiting NCT03743272 - Repeatability and Reproducibility of Multiparametric MRI
Completed NCT03979053 - Quantitative Magnetic Resonance Imaging to Aid Clinical Decision Making in Autoimmune Hepatitis.
Not yet recruiting NCT04902807 - Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
Recruiting NCT04933292 - A Randomised Clinical Trial Assessing the Efficacy and Safety of Mycophenolate Mofetil Versus Azathioprine for Induction of Remission in Treatment Primary Biliary Cholangitis-Autoimmune Hepatitis Overlap Syndrome Phase 4
Not yet recruiting NCT06455280 - SIPLIZUMAB in AILD and LT Phase 1